Login to Your Account

Other News To Note

Friday, January 6, 2012

• Tivorsan Pharmaceuticals Inc., of Providence, R.I., said the Muscular Dystrophy Association awarded it $1 million to help speed preclinical work needed before filing an investigational new drug application for a recombinant humanized form of biglycan in Duchenne's muscular dystrophy (DMD). Tivorsan's approach looks to treat DMD by up-regulating the utrophin protein and its candidate, TVN-102, previously demonstrated a reduction in muscle damage, muscle degeneration and improved muscle function in a mouse model.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription